Further Experience with the “No-React” Bioprosthesis in Patients with Active Infective Endocarditis: 11-Year Single Center Results in 402 Patients

Abstract

Objectives We investigated early, midterm, and long-term results following valve replacement with the “No-React” bioprosthesis in patients with active infective endocarditis (AIE).

Patients and Methods Between February 2000 and February 2011, a total of 402 patients (median 61 years, 17 to 91 years) received “No-React” bioprostheses due to single valve AIE in 315 (aortic valve replacement n = 158, aortic conduit n = 30, mitral valve replacement n = 116, tricuspid valve replacement n = 11) and double valve AIE in 87 cases. Prosthetic AIE was found in 105 patients (26.1%). Mean follow-up was 2.8 ± 3.2 years (1 month to 11.4 years) with 1,124 patient years, completed in 97.1%. This retrospective study analyzes both prospectively updated data (n = 255) and patients recently operated upon (n = 147).

Results There was a highly significant difference in the survival between patients operated on urgently and patients operated on in an emergency (30-day, 1-, 5-, and 10-year survival were 80.9 ± 2.3%, 63.8 ± 2.9%, 48.3 ± 3.3%, and 39.7 ± 4.1% vs. 61.3 ± 4.5%, 45.0 ± 4.7%, 33.1 ± 4.6%, and 14.0 ± 5.1%, respectively, p < 0.001), due to native versus prosthetic AIE (p = 0.032), single versus double valve replacement (p = 0.005), and with or without abscess formation (p < 0.001). Thirty-day, 1-, 5-, and 10-year freedom from reoperation due to recurrent endocarditis were 100%, 95.1 ± 1.4%, 86.4 ± 2.6%, and 82.1 ± 3.6% and due to structural valve deterioration (SVD) were 100%, 100%, 98.9 ± 0.8%, and 91.4 ± 4.0%, respectively. There was no difference in prosthesis durability between the older (> 60 years) and the younger patients.

Conclusions Our experience in the use of “No-React” bioprostheses in patients with native and prosthetic AIE shows satisfactory early, midterm, and long-term results, in particular low rates of reoperation due to recurrent endocarditis and SVD. Because these prostheses are readily available and their implantation straightforward, we strongly recommend their use in patients with AIE. Patients' survival differed significantly depending on their surgical urgency. Early mortality was independently predicted by septic shock, abscess formation, and number of implanted valves besides age per 10 years.

Keywords

infective endocarditis - surgery - bioprosthesis

Note

This study was presented at a lecture held at the 41st Annual Meeting of the German Society for Thoracic and Cardiovascular Surgery, Freiburg, February 13, 2012.

• References

• 1 Hoen B, Alla F, Selton-Suty C , et al; Association pour l'Etude et la Prévention de l'Endocardite Infectieuse (AEPEI) Study Group. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA 2002; 288 (1) 75-81
• 2 Tornos P, Iung B, Permanyer-Miralda G , et al. Infective endocarditis in Europe: lessons from the Euro heart survey. Heart 2005; 91 (5) 571-575
• 3 Musci M, Weng Y, Hübler M , et al. Homograft aortic root replacement in native or prosthetic active infective endocarditis: twenty-year single-center experience. J Thorac Cardiovasc Surg 2010; 139 (3) 665-673
• 4 Moon MR, Miller DC, Moore KA , et al. Treatment of endocarditis with valve replacement: the question of tissue versus mechanical prosthesis. Ann Thorac Surg 2001; 71 (4) 1164-1171
• 5 Leyh RG, Knobloch K, Hagl C , et al. Replacement of the aortic root for acute prosthetic valve endocarditis: prosthetic composite versus aortic allograft root replacement. J Thorac Cardiovasc Surg 2004; 127 (5) 1416-1420
• 6 Abolhoda A, Yu S, Oyarzun JR , et al. No-react detoxification process: a superior anticalcification method for bioprostheses. Ann Thorac Surg 1996; 62 (6) 1724-1730
• 7 Siniawski H, Grauhan O, Hofmann M , et al. Factors influencing the results of double-valve surgery in patients with fulminant endocarditis: the importance of valve selection. Heart Surg Forum 2004; 7 (5) E405-E410
• 8 Siniawski H, Lehmkuhl H, Weng Y , et al. Stentless aortic valves as an alternative to homografts for valve replacement in active infective endocarditis complicated by ring abscess. Ann Thorac Surg 2003; 75 (3) 803-808 , discussion 808
• 9 Musci M, Siniawski H, Pasic M , et al. Surgical therapy in patients with active infective endocarditis: seven-year single centre experience in a subgroup of 255 patients treated with the Shelhigh stentless bioprosthesis. Eur J Cardiothorac Surg 2008; 34 (2) 410-417
• 10 David TE, Gavra G, Feindel CM, Regesta T, Armstrong S, Maganti MD. Surgical treatment of active infective endocarditis: a continued challenge. J Thorac Cardiovasc Surg 2007; 133 (1) 144-149
• 11 Thuny F, Grisoli D, Collart F, Habib G, Raoult D. Management of infective endocarditis: challenges and perspectives. Lancet 2012; 379 (9819) 965-975
• 12 Kang DH, Kim YJ, Kim SH , et al. Early surgery versus conventional treatment for infective endocarditis. N Engl J Med 2012; 366 (26) 2466-2473
• 13 Habib G, Hoen B, Tornos P , et al; ESC Committee for Practice Guidelines; Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J 2009; 30 (19) 2369-2413
• 14 Aksoy O, Sexton DJ, Wang A , et al. Early surgery in patients with infective endocarditis: a propensity score analysis. Clin Infect Dis 2007; 44 (3) 364-372
• 15 Vikram HR, Buenconsejo J, Hasbun R, Quagliarello VJ. Impact of valve surgery on 6-month mortality in adults with complicated, left-sided native valve endocarditis: a propensity analysis. JAMA 2003; 290 (24) 3207-3214
• 16 Tleyjeh IM, Abdel-Latif A, Rahbi H , et al. A systematic review of population-based studies of infective endocarditis. Chest 2007; 132 (3) 1025-1035
• 17 Bannay A, Hoen B, Duval X , et al; AEPEI Study Group. The impact of valve surgery on short- and long-term mortality in left-sided infective endocarditis: do differences in methodological approaches explain previous conflicting results?. Eur Heart J 2011; 32 (16) 2003-2015
• 18 Lalani T, Cabell CH, Benjamin DK , et al; International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators. Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis: use of propensity score and instrumental variable methods to adjust for treatment-selection bias. Circulation 2010; 121 (8) 1005-1013
• 19 Anguera I, Miro JM, Cabell CH , et al; ICE-MD investigators. Clinical characteristics and outcome of aortic endocarditis with periannular abscess in the International Collaboration on Endocarditis Merged Database. Am J Cardiol 2005; 96 (7) 976-981
• 20 Galiñanes M, Meduoye A, Ferreira I, Sosnowski A. Totally biological composite aortic stentless valved conduit for aortic root replacement: 10-year experience. J Cardiothorac Surg 2011; 6: 86
• 21 Dohmen PM, Gabbieri D, Lembcke A, Konertz W. Endothelial cell-seeded bovine internal mammary artery for complete revascularization. Ann Thorac Surg 2007; 83 (3) 1168-1169
• 22 Schmidtke C, Dahmen G, Sievers HH. Subcoronary Ross procedure in patients with active endocarditis. Ann Thorac Surg 2007; 83 (1) 36-39
• 23 Smedira NG, Blackstone EH, Roselli EE, Laffey CC, Cosgrove DM. Are allografts the biologic valve of choice for aortic valve replacement in nonelderly patients? Comparison of explantation for structural valve deterioration of allograft and pericardial prostheses. J Thorac Cardiovasc Surg 2006; 131 (3) 558-564 , e4
• 24 Carrel TP, Schoenhoff FS, Schmidli J, Stalder M, Eckstein FS, Englberger L. Deleterious outcome of No-React-treated stentless valved conduits after aortic root replacement: why were warnings ignored?. J Thorac Cardiovasc Surg 2008; 136 (1) 52-57
• 25 Kaya A, Heijmen RH, Kelder JC, Schepens MA, Morshuis WJ. Stentless biological valved conduit for aortic root replacement: initial experience with the Shelhigh BioConduit model NR-2000C. J Thorac Cardiovasc Surg 2011; 141 (5) 1157-1162
• 26 Musci M, Weng Y, Siniawski H , et al. Clinical results of the Shelhigh^® stentless bioprosthesis in patients with active infective endocarditis: 8-year single experience. In: Yankah CA, Weng Y, Hetzer R, , eds. Aortic Root Surgery: The Biological Solution. Heidelberg, Berlin; New York: Springer; 2010: 210-222